The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and informing industry through guidance as part of our ongoing efforts to increase access to needed medications, Iilun Murphy, MD, director of the Office of Generic Drugs in the FDAs Center for Drug Evaluation and Research, said in a statement
The GLP-1 era represents a genuine step change in what medicine can achieve for people with obesity
doi: 10.1016/j.jacc.2023.04.052 7 MalikRATesfayeSZieglerD
Eli Lilly Investment: $9 billion in new US manufacturing facilities specifically for obesity medications
The discussion is directed toward healthcare professionals familiar with endocrinology, reproductive medicine, and pharmacotherapeutics
doi: 10.3389/fgene.2021.639364 9 Rueda-LopesFCda CruzLCHFontesFLHerlingerALda Costa Ferreira JuniorOde AguiarRSet al